246 related articles for article (PubMed ID: 38263112)
21. Low Rates of Colonoscopy Follow-up After a Positive Fecal Immunochemical Test in a Medicaid Health Plan Delivered Mailed Colorectal Cancer Screening Program.
Green BB; Baldwin LM; West II; Schwartz M; Coronado GD
J Prim Care Community Health; 2020; 11():2150132720958525. PubMed ID: 32912056
[TBL] [Abstract][Full Text] [Related]
22. Increasing Fecal Immunochemical Test Return Rates by Implementing Effective "Reminder to Complete Kit" Communication With Participants: A Quality Improvement Study.
Prakash S; Merza N; Hosseini O; Ward H; Mansi T; Balducci M; Trammell D; Hernandez B; Obokhare I
Cureus; 2022 May; 14(5):e25169. PubMed ID: 35746986
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial).
Saito H; Kudo SE; Takahashi N; Yamamoto S; Kodama K; Nagata K; Mizota Y; Ishida F; Ohashi Y
Int J Colorectal Dis; 2020 May; 35(5):933-939. PubMed ID: 32034490
[TBL] [Abstract][Full Text] [Related]
24. Improving colorectal cancer screening in rural primary care: Preliminary effectiveness and implementation of a collaborative mailed fecal immunochemical test pilot.
Davis MM; Coury J; Larson JH; Gunn R; Towey EG; Ketelhut A; Patzel M; Ramsey K; Coronado GD
J Rural Health; 2023 Jan; 39(1):279-290. PubMed ID: 35703582
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of risk assessment and fecal immunochemical test in colorectal cancer screening: Results from a population-based program and meta-analysis.
Wang Z; Teng J; Wu W; Dou J; Wong MCS; Gong Y; Huang J; Gu K; Xu W
Cancer Med; 2023 Sep; 12(17):18189-18200. PubMed ID: 37578430
[TBL] [Abstract][Full Text] [Related]
26. Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.
Gupta S; Coronado GD; Argenbright K; Brenner AT; Castañeda SF; Dominitz JA; Green B; Issaka RB; Levin TR; Reuland DS; Richardson LC; Robertson DJ; Singal AG; Pignone M
CA Cancer J Clin; 2020 Jul; 70(4):283-298. PubMed ID: 32583884
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics.
Davis SN; Christy SM; Chavarria EA; Abdulla R; Sutton SK; Schmidt AR; Vadaparampil ST; Quinn GP; Simmons VN; Ufondu CB; Ravindra C; Schultz I; Roetzheim RG; Shibata D; Meade CD; Gwede CK
Cancer; 2017 Apr; 123(8):1390-1400. PubMed ID: 27906448
[TBL] [Abstract][Full Text] [Related]
29. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
[TBL] [Abstract][Full Text] [Related]
30. Design of a randomized controlled trial to assess the comparative effectiveness of a multifaceted intervention to improve three-year adherence to colorectal cancer screening among patients cared for in rural community health centers.
Davis TC; Morris JD; Reed EH; Curtis LM; Wolf MS; Davis AB; Arnold CL
Contemp Clin Trials; 2022 Feb; 113():106654. PubMed ID: 34906745
[TBL] [Abstract][Full Text] [Related]
31. Financial Incentives to Increase Colorectal Cancer Screening Uptake and Decrease Disparities: A Randomized Clinical Trial.
Green BB; Anderson ML; Cook AJ; Chubak J; Fuller S; Kimbel KJ; Kullgren JT; Meenan RT; Vernon SW
JAMA Netw Open; 2019 Jul; 2(7):e196570. PubMed ID: 31276178
[TBL] [Abstract][Full Text] [Related]
32. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study).
González-López N; Quintero E; Gimeno-Garcia AZ; Bujanda L; Banales J; Cubiella J; Salve-Bouzo M; Herrero-Rivas JM; Cid-Delgado E; Alvarez-Sanchez V; Ledo-Rodríguez A; de-Castro-Parga ML; Fernández-Poceiro R; Sanromán-Álvarez L; Santiago-Garcia J; Herreros-de-Tejada A; Ocaña-Bombardo T; Balaguer F; Rodríguez-Soler M; Jover R; Ponce M; Alvarez-Urturi C; Bessa X; Roncales MP; Sopeña F; Lanas A; Nicolás-Pérez D; Adrián-de-Ganzo Z; Carrillo-Palau M; González-Dávila E;
PLoS Med; 2023 Oct; 20(10):e1004298. PubMed ID: 37874831
[TBL] [Abstract][Full Text] [Related]
33. Colorectal Cancer Screening After Sequential Outreach Components in a Demographically Diverse Cohort.
Podmore C; Selby K; Jensen CD; Zhao WK; Weiss NS; Levin TR; Schottinger J; Doubeni CA; Corley DA
JAMA Netw Open; 2024 Apr; 7(4):e245295. PubMed ID: 38625704
[TBL] [Abstract][Full Text] [Related]
34. Impact of colorectal cancer screening on incidence, mortality and surgery rates: Evidences from programs based on the fecal immunochemical test in Italy.
Zorzi M; Urso EDL
Dig Liver Dis; 2023 Mar; 55(3):336-341. PubMed ID: 35999134
[TBL] [Abstract][Full Text] [Related]
35. Social determinants and participation in fecal occult blood test based colorectal cancer screening: A qualitative systematic review and meta-synthesis.
Marinucci N; Moy N; Koloski N; Shah A; Austin G; Russell-Bennett R; McGraw J; Dulleck U; Holtmann G
Health Promot J Austr; 2024 Jan; 35(1):9-36. PubMed ID: 37039425
[TBL] [Abstract][Full Text] [Related]
36. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Perdue LA; Henrikson NB; Bean SI; Blasi PR
JAMA; 2021 May; 325(19):1978-1998. PubMed ID: 34003220
[TBL] [Abstract][Full Text] [Related]
37. Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.
Cusumano VT; May FP
J Gen Intern Med; 2020 Jun; 35(6):1870-1874. PubMed ID: 32128688
[TBL] [Abstract][Full Text] [Related]
38. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
[TBL] [Abstract][Full Text] [Related]
39. How effects on health equity are assessed in systematic reviews of interventions.
Welch V; Dewidar O; Tanjong Ghogomu E; Abdisalam S; Al Ameer A; Barbeau VI; Brand K; Kebedom K; Benkhalti M; Kristjansson E; Madani MT; Antequera Martín AM; Mathew CM; McGowan J; McLeod W; Park HA; Petkovic J; Riddle A; Tugwell P; Petticrew M; Trawin J; Wells GA
Cochrane Database Syst Rev; 2022 Jan; 1(1):MR000028. PubMed ID: 35040487
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
